Kinase Profiling Inhibitor Database

Inhibitor Structure Image Brutto MW Target Reference Reference 2
MRT199665 C28H31N5O2.ClH 506.04 MARK Clark K. (2012) Proc Natl Acad Sci USA 109(42) 16986-91
MRT67307 C26H36N6O2 464.60 IKKε, TBK1 Clark K. (2011) Biochem. J. 434 93-104
MSC 2032964A C16H13F3N6O 362.31 ASK1 Guo X. (2010) EMBO Molecular Medicine 2 504-515
Necrostatin-1 (Nec-1) C13H13N3OS 259.33 RIP Degterev A. Hitomi J. (2008) Nature Chemical Biology 4 313-321
Nectrostatin-1 (Nec-1 inactive analog) C12H11N3OS 245.3 RIP Degterev A. Hitomi J. (2008) Nature Chemical Biology 4 313-321
NIK-Novartis-T1-7 C18H14N6OS 362.41 NIK
Novartis 12a (PKD1) C23H29F3N6O3 494.51 PKD1 Meredith E.L. (2010) J.Med.Chem. 53 5422-5438
NVP-BEZ 235 C30H25Cl2N5O 542.46 PI3K, Akt, mTOR Maira S. Stauffer F. (2008) Mol. Cancer. Ther. 7 1851-1863.
PCI-32765 (Ibrutinib) C25H24N6O2 440.5 Btk Honigberg L.A. (2010) Proc Natl Acad Sci 107 13075-13080
PD 0325901 C16H14F3IN2O4 482.19 MEK1 Bain J. (2007) Biochem J. 408 297–315. Barrett SD. (2008) Bioorg. Med. Chem. Lett. 18 6501-6504.
PD 0325901-Cl (CI-1055-R) C16H14O4N2F2ClI 498.65 MEK1
PD 0325901-Cl (CI-1055-Racemic mix of isomers) C16H14O4N2F2ClI 498.65 MEK1
PD 0325901-Cl (CI-1055-S) C16H14O4N2F2ClI 498.65 MEK1
PD 0332991 C24H30ClN7O2 483.99 CDK4, CDK6 Toogood P.L. (2005) J.Med.Chem. 48 2388-2406.
PD 184352 (CI-1040) C17H14ClF2IN2O2 478.66 MEK1, Yes1, ERK1 Mayes PA. (2013) Int J Cancer. E149-57
PF3644022 C21H18N4OS 374.46 MAPKAPK2 Mourey (2010) J.Pharmacol.Exp.Ther. 333 797
PI-103 C19H16N4O3 348.36 PI3K Samuels Y. (2004) Science 304 554
PLX 4720 (Raf Kinase Inhibitor V) C17H14ClF2N3O3S 413.83 B-Raf Tsai J. (2008) Proc Natl Acad Sci USA. 3041-6
PP2 C15H16ClN5 301.77 Src Kirihara T. (2013) Exp Eye Res. S0014
Princeton's TrkA inhibitor compound 20h C24H24BrF3N6O4S2 661.52 Trk A Kim S.H. Tokarski J.S. (2008) Bioorg. Med. Chem. Lett. 18 634-639
PS-1145 C17H11ClN4O 322.75 IKK Castro A.C. (2003) Bioorg. Med. Chem. Lett. 13 2419-2422.
Purvalanol B C20H25ClN6O3 432.9 CDK
Rigel TRAF6 Inhibitor C16H12ClF4N5O3S 465.81 TRAF6
SGK-Sanofi-14i C18H15ClN6O3S 430,.87 SGK Halland, N (2015) ACS Medicinal Chemistry Letters 6 73-78
SGK1-Sanofi-14g C17H12Cl2N6O2S 435.29 SGK Halland, N (2015) ACS Medicinal Chemistry Letters 6 73-78
SGK1-Sanofi-14h C17H12Cl2N6O2S 435.29 SGK Halland, N (2015) ACS Medicinal Chemistry Letters , 6,73-78
SGK1-Sanofi-14n C17H12CIFN6O2S 418.83 SGK Halland, N (2015) ACS Medicinal Chemistry Letters 6 73-78
SGK1-Sanofi-308-R C23H23FN6O4S 498.53 SGK1
SGK1-Sanofi-308-S C23H23FN6O4S 498.53 SGK1
SGK1-Sanofi-ex.290-R C24H25ClN6O5S 545.01 SGK1
SGK1-Sanofi-ex.290-S C24H25ClN6O5S 545.01 SGK1
SRT 1720 C27H24F3N7O3S 583.59 SIRT1 Milne J.C. Lambert P.D. Schenk S. (2007) Nature 450 712-716
SU-6668 C18H18N2O3 310.35 Aurora Godl K. (2005) Cancer Res. 65 6919-6926.
TG003 C13H15NO2S 249.33 Cdc2-like kinase Muraki M. (2004) J. Biol. Chem. 279 24246-24254
VPS34-IN1 C21H24ClN7O 425.91 Vps34 Bago R (2014) Biochem J.
VPS34-IN2 (PIK-III) C17H17N7 319.36 PI3K, VPS34 William E. Dowdle (2014) Nature Cell Biology
VX-680 C23H28N8OS 464.59 Aurora Harrington E.A. (2004) Nature Medicine 10 262
VX-745 C19H9Cl2F2N3OS 436.26 p38 MAPK Tsai YR Epub 2013 Jan 21 Eur J Pharmacol. 2013 Feb 15 701(1-3) 96-105
WNK-463 C21H24F3N7O2 463.46 WNK Yamada K (2016) Nat Chem Biol. 12(11) 896-898
Wyeth PDK1 Inhibitor Compound 1 C19H22Cl4N4O2 480.21 PDK1 Gopalsamy A. (2007) Journal of Medicinal Chemistry 50 (23) 5547-5549

Pages

Do you need any help? Please get in touch and we’ll be happy to lend a hand.